158
Participants
Start Date
April 14, 2023
Primary Completion Date
November 30, 2026
Study Completion Date
November 30, 2026
ELI-002 7P
ELI-002 Amph-CpG-7909 admixed with ELI-002 Amph-Peptides 7P administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
Memorial Sloan Kettering Cancer Center, New York
New York Presbyterian Weill Cornell Medical Center, New York
Northwell Health, Lake Success
Lehigh Valley Health Network, Allentown
University of Pennsylvania, Philadelphia
Emory Winship Cancer Institute, Atlanta
Mayo Clinic Comprehensive Cancer Center, Jacksonville
University of Florida Health Cancer Center, Gainesville
University of Miami, Coral Gables
Moffitt Cancer Center, Tampa
Sarah Cannon Research Institute, Nashville
Vanderbilt University Medical Center, Nashville
University of Michigan, Ann Arbor
University of Iowa, Iowa City
Medical College of Wisconsin, Milwaukee
Mayo Clinic Comprehensive Cancer Center, Rochester
Ochsner Health, New Orleans
University of Texas Southwestern, Dallas
The University of Texas MD Anderson Cancer Center, Houston
University of Colorado Hospital-Anschutz Cancer Pavillion, Aurora
Mayo Clinic Comprehensive Cancer Center, Phoenix
Banner MD Anderson Cancer Center, Gilbert
Cedars-Sinai Medical Center, Los Angeles
University of California Los Angeles, Los Angeles
City of Hope, Duarte
University of California, Irvine, Orange
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Lead Sponsor
Elicio Therapeutics
INDUSTRY